{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:55:02Z","timestamp":1762509302871,"version":"3.44.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.7759\/cureus.92951","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:16:37Z","timestamp":1758568597000},"source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-Induced Warm Autoimmune Hemolytic Anemia and Pancytopenia"],"prefix":"10.7759","author":[{"given":"Matthew","family":"Baron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Amisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiranpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586426","article-title":"Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review","volume":"16","author":"Hernandez-Martinez JM","year":"2025","unstructured":"Hernandez-Martinez JM, Rios-Garcia E, Palomares-Palomares CB, Arrieta O. Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review. Front Immunol. 2025, 16:1586426. 10.3389\/fimmu.2025.1586426","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017, 35:785-92. 10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy N","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al.. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019, 6:e48-57. 10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.018","article-title":"Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma","volume":"119","author":"Tokumo K","year":"2018","unstructured":"Tokumo K, Masuda T, Miyama T, et al.. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer. 2018, 119:21-4. 10.1016\/j.lungcan.2018.02.018","journal-title":"Lung Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350209-nivolumab-induced-warm-autoimmune-hemolytic-anemia-and-pancytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:16:38Z","timestamp":1758568598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350209-nivolumab-induced-warm-autoimmune-hemolytic-anemia-and-pancytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.92951","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}